 Home > Biochemistry News > Biotechnology News > Innovative Mechanism of Action Novartis Leukemia Therapy Receives FDA Approval

Innovative Mechanism of Action Novartis Leukemia Therapy Receives FDA Approval

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

acute myelomonocytic leukemia

ph 10

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 30, Novartis announced that the US FDA approved Scemblix (asciminib) for the treatment of two different indications for chronic myeloid leukemia (CML)

CML is a malignant myeloproliferative tumor that occurs in pluripotent hematopoietic stem cells.

Scemblix is an allosteric inhibitor against ABL1, which inhibits the activity of BCR-ABL1 by binding to the myristoyl pocket of ABL1

▲Scemblix's mechanism of action (picture source: reference [2])

This approval is based on the results of a phase 3 clinical trial and a phase 1 clinical trial

Note: The original text has been deleted

Reference materials:

[1] FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia.

[2] Hughes, et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express Innovative Mechanism of Action, Novartis Leukemia Therapy Receives FDA Approval Today

11-15

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Innovative Mechanism of Action Novartis Leukemia Therapy Receives FDA Approval

Related Articles

Express Innovative Mechanism of Action, Novartis Leukemia Therapy Receives FDA Approval Today